Cargando…

PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?

Poly (ADP-ribose) polymerase (PARP) inhibitors (iPARPs) have shown efficacy in homologous recombination (HR) deficiency patients with advanced castration resistant prostate cancer and have shown a radiosensitizing effect in preclinical and early clinical trials. Preclinical data in prostate cancer c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angel, Martin, Zarba, Martin, Sade, Juan Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816501/ https://www.ncbi.nlm.nih.gov/pubmed/35211207 http://dx.doi.org/10.3332/ecancer.2021.ed118

Ejemplares similares

Experience of bipolar androgen therapy (BAT) in Argentinian oncology centres
por: Zarbá, Martín, et al.
Publicado: (2022)

A Promising Future for Prostate Cancer Diagnostics
por: Assinder, Stephen J., et al.
Publicado: (2017)

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models
por: Guillot, Clément, et al.
Publicado: (2014)

PARP inhibition and immunotherapy: a promising duo in fighting cancer
por: Phillipps, Jordan, et al.
Publicado: (2023)

BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy
por: Soni, Aashish, et al.
Publicado: (2022)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
por: Klotz, Daniel Martin, et al.
Publicado: (2020)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
por: Curtin, Nicola, et al.
Publicado: (2020)

Prostate cancer and PARP inhibitors: progress and challenges
por: Teyssonneau, Diego, et al.
Publicado: (2021)

Checkpoint and PARP inhibitors, for whom and when
por: Lee, Jung-Min, et al.
Publicado: (2017)

Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib
por: Gravells, Polly, et al.
Publicado: (2018)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
por: Congregado, Belén, et al.
Publicado: (2022)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation
por: Waissi, Waisse, et al.
Publicado: (2021)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

Geroprotection: A promising future
por: Magon, Navneet, et al.
Publicado: (2012)

Microalgae: A Promising Future
por: Caroppo, Carmela, et al.
Publicado: (2022)

Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
por: Divan, Ali, et al.
Publicado: (2020)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
por: Teyssonneau, Diego, et al.
Publicado: (2022)

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015)

PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
por: Pu, Jun, et al.
Publicado: (2020)

PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
por: Pu, Jun, et al.
Publicado: (2022)

Breast cancer: current state and future promise
por: Chodosh, Lewis A
Publicado: (2011)

Rotavirus Vaccine: A Promise for the Future
por: Zaman, K.
Publicado: (2008)

Asthma: still a promising future?
por: Chanez, Pascal, et al.
Publicado: (2014)

Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor scheduling
por: Strobl, Maximilian, et al.
Publicado: (2023)

PARP inhibitors in the management of breast cancer: current data and future prospects
por: Livraghi, Luca, et al.
Publicado: (2015)

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
por: Virtanen, Verneri, et al.
Publicado: (2019)

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
por: McNevin, Ciara S., et al.
Publicado: (2022)

Use of PARP inhibitors in prostate cancer: from specific to broader application
por: Zhang, Zhenting, et al.
Publicado: (2023)

Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review)
por: Rivero Belenchón, Inés, et al.
Publicado: (2023)

A strong start, a promising future
Publicado: (2011)

Radiosensitization in prostate cancer: mechanisms and targets
por: Palacios, Diego A, et al.
Publicado: (2013)

Nanoparticle-Based Radiosensitization
por: Kempson, Ivan
Publicado: (2020)

Nanoparticle-Based Radiosensitization
por: Kempson, Ivan
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nb8g0ii2vn8ephdfr2of668g2n